SEATTLE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of CAR T cells, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference taking place January 13-16, 2025, in San Francisco, CA.
Presentation Date/Time: Wednesday, January 15, 2025 at 2:30 p.m. PT
Presentation Location: Golden Gate (32nd Floor) The Westin
Presenting Speaker: Andrew Scharenberg, M.D, co-founder and Chief Executive Officer
About Umoja Biopharma
Umoja Biopharma, Inc. is a clinical-stage biotechnology company aiming to develop in vivo cell therapies that improve the reach, effectiveness, and access of CAR T cell therapies in both oncology and autoimmunity. Umoja's VivoVec™ in vivo gene delivery technology empowers a patient's own immune system to fight disease. Enabling its core technology is the Company's state-of-the-art lentiviral vector development and manufacturing facility in Louisville, Colorado. Umoja believes its approach can provide broader access and improved effectiveness of the most advanced immunotherapies, enabling more patients to live better, fuller lives. To learn more, connect with Umoja on LinkedIn and visit http://umoja-biopharma.com/.
Investors
Grace Kim, PhD
Head of Investor Relations
Media
Matt Wright
Real Chemistry
